Immunotherapy combined with chemotherapy for patients with pulmonary large cell neuroendocrine carcinoma

The efficacy of ICIs combined with chemotherapy or chemotherapy alone was evaluated according to the Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) and RECIST version 1.1, and the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were determined. Median PFS and OS were assessed by the Kaplan–Meier (K–M) method, and the log-rank test was used to assess the differences in survival between the two groups. The median PFS of the EC group and the other group was both 6.5 months, and there was no significant difference in PFS between the two groups (P = 0.770) [Supplementary Figure 1A, http://links.lww.com/CM9/C93]. [...]our study suggests that immunotherapy should not be recommended for patients with PD-L1 ≤1%.